BCM
TVRD

BlueCrest Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

BlueCrest Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-304
Closed -$150K – 1150
2017
Q3 		$150K Buy
+304
New +$152K 0.01% 772

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlueCrest Capital Management's TVRD Position: Q4 2017 in Review

BlueCrest Capital Management sold out of Tvardi Therapeutics (TVRD) in Q4 2017, closing a stake of 304 shares — an estimated $150K sold.

BlueCrest Capital Management first reported a position in TVRD in Q3 2017 and held it in 1 quarter. The position peaked at $150K in Q3 2017. 127 funds tracked by Wall St. Rank hold TVRD as of Q4 2017.

  • BlueCrest Capital Management reported no remaining Tvardi Therapeutics position as of Q4 2017 after selling out during the quarter.
  • BlueCrest Capital Management sold 304 Tvardi Therapeutics shares in Q4 2017, an estimated $150K.
  • BlueCrest Capital Management first reported a position in Tvardi Therapeutics in Q3 2017 and held it in 1 quarter.
  • BlueCrest Capital Management's Tvardi Therapeutics position peaked at $150K in Q3 2017.
  • 127 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2017.

Based on BlueCrest Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.